Klow vs Glow peptide: what KPV adds and what is known

The short answer: Klow is Glow plus KPV. Both are marketed as injectable peptide mixes. Glow is described as GHK-Cu, BPC-157, and TB-500, and Klow adds KPV, a three-amino-acid fragment of alpha-MSH studied for gut inflammation in mice. [7] No published study has tested either blend, in people or in animals. Everything said about them is extrapolated from separate studies of each ingredient, and almost all of those studies are in animals.

Neither mix has a lawful prescription path in the United States today, because both contain injectable GHK-Cu, which is not on the 503A bulks list. [9] This post compares the two component by component. It does not give doses, and it does not recommend either one.

What is in Klow vs Glow?

Blend labels vary, and the amounts in any vial are not standardized or verified by a regulator. The commonly described recipes are:

So the question "Klow vs Glow" is really one question: does adding KPV change anything? To answer it, you need to know what each of the four ingredients has and has not shown.

What does GHK-Cu do in Glow and Klow?

GHK-Cu is a copper-binding tripeptide found in human plasma. It is the reason both blends are marketed for skin. Its human evidence comes from small controlled cosmetic studies of topical creams that reported tighter skin, better elasticity and density, and fewer fine lines, summarized in reviews written largely by the peptide's discoverer. [1] Animal studies show faster wound healing in rats, mice, pigs, and dogs. [1] Reviews also report gene expression and cell data suggesting broad effects on repair and inflammation pathways. [2]

None of that human evidence involves injection. There is no human trial of injected GHK-Cu for any condition, which is why the skin claims for Glow and Klow borrow from a different route than the one in the vial. We cover that gap in topical vs injectable GHK-Cu.

What do BPC-157 and TB-500 add?

These two are the Wolverine half of both blends.

• BPC-157 has the most tissue-specific animal work. In a 2011 rat study it sped healing of a cut Achilles tendon and increased tendon cell outgrowth, survival, and migration. [3] A 2019 review found consistent rodent results and said efficacy is yet to be confirmed in humans. [4] Human data are three small uncontrolled pilot reports with no control group; no randomized trial has reported. [13]
• TB-500 is sold as a synthetic version or fragment of thymosin beta-4. In a rat skin wound model, thymosin beta-4 increased wound closure by 42% at day 4 and up to 61% at day 7. [5] Full-length thymosin beta-4 has small phase 1 and phase 2 human trials (IV safety, eye drops for dry eye, topical gel for skin ulcers). None tested injected TB-500 for injury healing. [6] [14] [15]

For how these two compare on their own, see BPC-157 vs TB-500 and BPC-157 vs GHK-Cu.

What is KPV, and what does it add to Klow?

KPV is the tripeptide lysine-proline-valine, the tail end of alpha-melanocyte stimulating hormone. It is the "K" that turns Glow into Klow, and it is marketed for inflammation of the gut and skin.

Its evidence is two 2008 mouse studies from independent labs:

• Oral KPV in drinking water reduced the severity of chemically induced colitis in mice and lowered inflammatory cytokines, working through the PepT1 transporter in the gut lining. [7]
• In two other mouse colitis models, KPV led to earlier recovery, regained body weight, and fewer inflammatory cells in the colon. [8]

That is the whole evidence base. No human trial of KPV has been published for any condition, no study has given KPV by injection alongside the other three peptides, and the mouse studies used oral delivery for gut inflammation, not injection for skin or recovery. A direct comparison with BPC-157 is on BPC-157 vs KPV.

What KPV adds, honestly stated: one more ingredient with mouse data for colitis, and one more unknown for safety and interaction.

Is Klow better than Glow?

There is no way to know, and anyone who says otherwise is guessing. No study has compared the two, no study has tested either one, and no study has tested KPV combined with any of the other three peptides.

When people report that Klow "works better" for skin, gut comfort, or recovery, several things could explain it: the different mix, a different product with different purity, expectation, or ordinary healing over time. Only a controlled trial can separate those, and none exists. If you want to read an individual study critically, our guide on how to read a peptide study explains what to look for.

How do Klow and Glow relate to the Wolverine stack?

The three blends nest inside one another:

• Wolverine stack: BPC-157 plus TB-500, marketed for recovery.
• Glow: the Wolverine pair plus GHK-Cu, marketed for skin and recovery.
• Klow: Glow plus KPV, marketed for skin, recovery, and inflammation.

Each step adds an ingredient with its own animal data, and each step adds another substance with no human injected safety data. None of the three combinations has been studied as a combination. The combination question is covered in more detail in peptide stacks, and claims about visible results are compared with measured outcomes in peptide before and after.

Are Klow and Glow legal?

A blend is only as lawful as its strictest ingredient. [9] Here is where each ingredient stands as of September 2026:

• GHK-Cu (injectable): FDA lists injectable GHK-Cu as a withdrawn 503A nomination. It is off Category 2 but not on the bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. [9] Topical GHK-Cu in a cosmetic is a separate, lawful product as long as it makes only cosmetic claims. [11] Track it on the GHK-Cu regulatory page.
• BPC-157, TB-500, and KPV: the Pharmacy Compounding Advisory Committee recommended adding all three to the 503A bulks list in July 2026, but FDA has not published a final rule. [10] Follow KPV on the KPV regulatory page.

Because both blends contain injectable GHK-Cu, neither Klow nor Glow has a lawful prescription path today. Products labeled "research use only" are not lawful for human use, and their contents are not verified. There is no lawful compounded price to report; the KPV cost page explains why advertised prices are not comparable. State rules on compounding and telehealth are on our state law pages.

For the peptides that can be prescribed lawfully today, see how to get peptides prescribed. Our peptide therapy explainer explains why a clinic offering a blend is not the same as a lawful product.

Can athletes use Klow or Glow?

No, if they are tested. WADA names thymosin beta-4 and TB-500 in section S2, and unapproved substances such as BPC-157 and KPV fall under section S0. [12] A single prohibited ingredient makes the whole blend a doping risk.

What are the side effects of Klow and Glow?

Nobody knows for either blend. No human study has measured side effects of injected GHK-Cu, BPC-157, TB-500, or KPV, alone or together. [4] Reviews of GHK-Cu report both pro-repair activity and effects on cell growth in lab studies, so its effect on existing tumors is unresolved. [2] Mixing four unapproved peptides in one vial also adds questions about stability, contamination, and dose accuracy that no regulator has checked.

The takeaway

Klow is Glow plus KPV. The difference between them is one ingredient with mouse colitis data. Neither blend has been tested, neither has a lawful prescription path today, and the parts with the best human evidence (topical GHK-Cu on skin) do not come from the route these blends use. We will update this page if a study of either blend, or a final FDA rule on any ingredient, is published.